Seattle Genetics files sBLA for Adcetris in relapsed Hodgkin lymphoma and systemic ALCL
19 March 2013
FDA grants Seattle Genetics' Adcetris orphan rating in MF
27 November 2012
Takeda debuts Hodgkin lymphoma drug Adcetris in UK
19 November 2012
European Commission grants conditional approval for Adcetris
1 November 2012
More highlights from ESMO Congress
2 October 2012
“Black box” warning for Seattle Genetics’ Adcetris
16 January 2012
Showing 1-13 of 13 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
